CALL - SPRINTER OPEN END - MEDTRONIC Stock

Certificat

DE000VM3D5J9

Delayed Deutsche Boerse AG 13:52:38 2024-06-26 EDT
1.22 EUR -2.40% Intraday chart for CALL - SPRINTER OPEN END - MEDTRONIC
Current month-6.72%
1 month-13.19%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-06-26 1.22 -2.40%
24-06-25 1.25 -6.02%
24-06-24 1.33 -0.75%
24-06-21 1.34 +6.35%
24-06-20 1.26 +6.78%

Delayed Quote Deutsche Boerse AG

Last update June 26, 2024 at 01:52 pm

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellCALL
Underlying MEDTRONIC PLC
IssuerLogo Issuer Vontobel Vontobel
WKN VM3D5J
ISINDE000VM3D5J9
Date issued 2023-10-04
Strike 66.97 $
Maturity Unlimited
Parity 10 : 1
Emission price 1.25
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 2.21
Lowest since issue 0.5
Spread 0.01
Spread %0.80%

Company Profile

Medtronic plc is one of the world leaders in designing, manufacturing and marketing of medical equipment. Net sales break down by sector of activity as follows: - general and minimally invasive surgery (28.8%): surgical equipment, intra-operative monitoring systems, ventilation systems, etc.; - cardiac rhythm management (18.6%): implantable cardiac pacemakers, implantable defibrillators and automatic external defibrillators, cardiac ablation probes, etc.; - vascular diseases and cardiac surgery (17.4%): coronary stents, endoprostheses for aortal pathologies, distal protection systems, catheters, heart valve prostheses, auto-transfusion equipment, cardiac ablation devices, etc.; - spinal disorders (14.1%): spinal prostheses, disc prostheses, cerebral stimulation systems, bone graft technologies and mini-invasive spinal surgery, etc. The group also develops medical imagery-guided surgical navigation systems activity; - neurovascular, ear, nose and throat (ENT) and pelvic diseases (8.2%); - diabetes management (7.4%): internal and external glycemia monitoring systems and insulin pumps; - neurological disorders (5.5%): neurostimulation and pumped medication administration products, diagnostic tools, etc. Net sales are distributed geographically as follows: Ireland (0.3%), the United States (50.9%) and other (48.8%).
Sector
-
More about the company

Ratings for Medtronic plc

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: Medtronic plc

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
80.41 USD
Average target price
94.02 USD
Spread / Average Target
+16.93%
Consensus